Table of Content

1 INTRODUCTION (Page No. - 31)
    1.1 STUDY OBJECTIVES 
    1.2 CHEMILUMINESCENCE IMMUNOASSAY INDUSTRY DEFINITION 
           1.2.1 INCLUSIONS AND EXCLUSIONS
    1.3 MARKET SCOPE 
           1.3.1 MARKETS COVERED
                    FIGURE 1 CHEMILUMINESCENCE IMMUNOASSAY MARKET SEGMENTATION
           1.3.2 GEOGRAPHICAL SCOPE
           1.3.3 YEARS CONSIDERED
    1.4 CURRENCY CONSIDERED 
    1.5 STAKEHOLDERS 
2 RESEARCH METHODOLOGY (Page No. - 36)
    2.1 RESEARCH APPROACH 
          FIGURE 2 RESEARCH DESIGN
           2.1.1 SECONDARY DATA
                    2.1.1.1 Key data from secondary sources
           2.1.2 PRIMARY DATA
                    2.1.2.1 Primary sources
                    2.1.2.2 Key data from primary sources
                    2.1.2.3 Key industry insights
                                FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY AND DEMAND SIDE PARTICIPANTS
                                FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS (SUPPLY SIDE): BY COMPANY TYPE, DESIGNATION, AND REGION
    2.2 MARKET SIZE ESTIMATION 
          FIGURE 5 REVENUE SHARE ANALYSIS ILLUSTRATION
          FIGURE 6 MARKET ESTIMATION FROM IVD MARKET
          FIGURE 7 MARKET ESTIMATION FROM IMMUNOASSAY MARKET
          FIGURE 8 CAGR PROJECTIONS: SUPPLY SIDE ANALYSIS OF MARKET
          FIGURE 9 TOP-DOWN APPROACH
    2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 
          FIGURE 10 DATA TRIANGULATION METHODOLOGY
    2.4 MARKET SHARE ANALYSIS 
    2.5 STUDY ASSUMPTIONS 
    2.6 RESEARCH LIMITATIONS 
    2.7 RISK ASSESSMENT 
          TABLE 1 RISK ASSESSMENT: MARKET
    2.8 GROWTH RATE ASSUMPTIONS 
    2.9 IMPACT OF RECESSION ON MARKET 
3 EXECUTIVE SUMMARY (Page No. - 51)
    FIGURE 11 CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2023 VS. 2028 (USD BILLION)
    FIGURE 12 CHEMILUMINESCENCE IMMUNOASSAY INDUSTRY, BY TECHNOLOGY, 2023 VS. 2028 (USD BILLION)
    FIGURE 13 MARKET, BY SAMPLE TYPE, 2023 VS. 2028 (USD BILLION)
    FIGURE 14 MARKET, BY APPLICATION, 2023 VS. 2028 (USD BILLION)
    FIGURE 15 MARKET, BY END USER, 2023 VS. 2028 (USD BILLION)
    FIGURE 16 GEOGRAPHICAL SNAPSHOT OF MARKET
4 PREMIUM INSIGHTS (Page No. - 57)
    4.1 CHEMILUMINESCENCE IMMUNOASSAY MARKET OVERVIEW 
          FIGURE 17 INCREASING INCIDENCE OF DISEASES AND TECHNOLOGICAL ADVANCEMENTS TO DRIVE MARKET
    4.2 NORTH AMERICA: CHEMILUMINESCENCE IMMUNOASSAY INDUSTRY, BY PRODUCT (2022) 
          FIGURE 18 CONSUMABLES SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2022
    4.3 GEOGRAPHICAL GROWTH OPPORTUNITIES IN MARKET 
          FIGURE 19 CHINA AND INDIA TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD
    4.4 MARKET: REGIONAL MIX 
          FIGURE 20 ASIA PACIFIC TO WITNESS HIGHEST GROWTH RATE DURING STUDY PERIOD
    4.5 MARKET: DEVELOPED VS. DEVELOPING MARKETS 
          FIGURE 21 DEVELOPING MARKETS TO REGISTER HIGHER GROWTH DURING STUDY PERIOD
5 MARKET OVERVIEW (Page No. - 62)
    5.1 INTRODUCTION 
    5.2 MARKET DYNAMICS 
          FIGURE 22 CHEMILUMINESCENCE IMMUNOASSAY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
           5.2.1 DRIVERS
                    5.2.1.1 Increasing incidences of chronic and infectious diseases globally
                                FIGURE 23 INCREASING INCIDENCES OF DIABETES (GLOBAL)
                                FIGURE 24 NUMBER OF PEOPLE WITH CHRONIC CONDITIONS IN US, 1995–2030 (MILLION INDIVIDUALS)
                    5.2.1.2 Advancements in improving chemiluminescence immunoassay technologies in recent years
                    5.2.1.3 Growth of biotechnology and biopharmaceutical industries
                    5.2.1.4 Rapid increase in geriatric population globally
                                FIGURE 25 GLOBAL GERIATRIC POPULATION, BY REGION, 2019 VS. 2050 (MILLION)
                    5.2.1.5 Shift toward personalized medicines and individualized treatment decisions
           5.2.2 RESTRAINTS
                    5.2.2.1 High cost of chemiluminescence systems and reagents
                    5.2.2.2 Lack of regular quality control procedures for monitoring and detecting cross-reactivity and interference
           5.2.3 OPPORTUNITIES
                    5.2.3.1 High growth prospects for players in emerging economies
                    5.2.3.2 Increasing number of collaborations and partnerships
           5.2.4 CHALLENGES
                    5.2.4.1 Unfavorable reimbursement scenario and budgetary constraints in healthcare systems
                    5.2.4.2 Lack of skilled professionals and aging workforce
    5.3 VALUE CHAIN ANALYSIS 
          FIGURE 26 VALUE CHAIN ANALYSIS: MAJOR VALUE ADDED DURING MANUFACTURING AND ASSEMBLY PHASES
    5.4 SUPPLY CHAIN ANALYSIS 
          FIGURE 27 DIRECT DISTRIBUTION TO BE PREFERRED STRATEGY FOR PROMINENT COMPANIES
    5.5 PORTER’S FIVE FORCES ANALYSIS 
          TABLE 2 HIGH CONSOLIDATION IN MARKET TO RESTRICT ENTRY OF NEW PLAYERS
           5.5.1 DEGREE OF COMPETITION
           5.5.2 BARGAINING POWER OF SUPPLIERS
           5.5.3 BARGAINING POWER OF BUYERS
           5.5.4 THREAT OF SUBSTITUTES
           5.5.5 THREAT OF NEW ENTRANTS
    5.6 KEY STAKEHOLDERS AND BUYING CRITERIA 
           5.6.1 KEY STAKEHOLDERS IN BUYING PROCESS
                    FIGURE 28 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR END USERS
                    TABLE 3 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR END USERS
           5.6.2 BUYING CRITERIA
                    FIGURE 29 KEY BUYING CRITERIA FOR MAJOR END USERS
                    TABLE 4 KEY BUYING CRITERIA, BY END USER
    5.7 REGULATORY LANDSCAPE 
           5.7.1 US
                    TABLE 5 US: CLASSIFICATION OF IMMUNOASSAY PRODUCTS
                    FIGURE 30 US: REGULATORY PROCESS FOR IVD DEVICES
           5.7.2 CANADA
                    FIGURE 31 CANADA: REGULATORY PROCESS FOR IVD DEVICES
           5.7.3 EUROPE
                    TABLE 6 EUROPE: CLASSIFICATION OF IVD DEVICES
           5.7.4 JAPAN
                    FIGURE 32 JAPAN: REGULATORY PROCESS FOR IVD DEVICES
                    TABLE 7 JAPAN: CLASSIFICATION OF IVD REAGENTS
                    TABLE 8 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
           5.7.5 CHINA
                    TABLE 9 CHINA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
           5.7.6 INDIA
                    FIGURE 33 INDIA: REGULATORY PROCESS FOR IVD DEVICES
           5.7.7 INDONESIA
                    TABLE 10 INDONESIA: REGISTRATION PROCESS FOR IVD DEVICES
           5.7.8 RUSSIA
                    TABLE 11 RUSSIA: CLASSIFICATION OF IVD DEVICES
           5.7.9 SAUDI ARABIA
                    TABLE 12 SAUDI ARABIA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
           5.7.10 MEXICO
                     FIGURE 34 MEXICO: REGULATORY PROCESS FOR IVD DEVICES
                     TABLE 13 MEXICO: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
           5.7.11 BRAZIL
                     FIGURE 35 BRAZIL: REGULATORY PROCESS FOR IVD DEVICES
           5.7.12 SOUTH KOREA
                     TABLE 14 SOUTH KOREA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
           5.7.13 MIDDLE EAST
           5.7.14 AFRICA
    5.8 TECHNOLOGY ANALYSIS 
          TABLE 15 RECENT PRODUCT LAUNCHES WITH ADVANCED TECHNOLOGIES IN CHEMILUMINESCENCE IMMUNOASSAY INDUSTRY
    5.9 TRADE ANALYSIS 
           5.9.1 TRADE ANALYSIS FOR CHEMILUMINESCENCE IMMUNOASSAYS
                    TABLE 16 IMPORT DATA FOR HS CODE 902780, BY COUNTRY, 2018–2022 (USD MILLION)
                    TABLE 17 EXPORT DATA FOR HS CODE 902780, BY COUNTRY, 2018–2022 (USD MILLION)
    5.10 ECOSYSTEM MAPPING 
           FIGURE 36 ECOSYSTEM MAPPING OF MARKET
           5.10.1 ROLE IN ECOSYSTEM
           5.10.2 KEY PLAYERS OPERATING IN MARKET
    5.11 PATENT ANALYSIS 
    5.12 KEY CONFERENCES AND EVENTS IN 2023–2024 
           TABLE 18 LIST OF CONFERENCES AND EVENTS IN 2023–2024
    5.13 PRICING ANALYSIS 
           5.13.1 AVERAGE SELLING PRICE, BY APPLICATION (KEY PLAYERS)
                     TABLE 19 PRICE RANGE OFFERED BY KEY PLAYERS, BY APPLICATION (USD)
    5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 
6 CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT (Page No. - 92)
    6.1 INTRODUCTION 
          TABLE 20 CHEMILUMINESCENCE IMMUNOASSAY INDUSTRY, BY PRODUCT, 2021–2028 (USD MILLION)
    6.2 CONSUMABLES 
           6.2.1 CONSUMABLES TO ACCOUNT FOR LARGEST SHARE OF MARKET DURING STUDY PERIOD
                    TABLE 21 LIST OF CHEMILUMINESCENCE IMMUNOASSAY CONSUMABLES AVAILABLE
                    TABLE 22 MARKET FOR CONSUMABLES, BY REGION, 2021–2028 (USD MILLION)
    6.3 INSTRUMENTS 
           6.3.1 INCREASING ADVANCES WITH HIGH-THROUGHPUT CAPACITIES AND GROWING AUTOMATION TRENDS TO DRIVE MARKET
                    TABLE 23 LIST OF CHEMILUMINESCENCE IMMUNOASSAY INSTRUMENTS AVAILABLE
                    TABLE 24 MARKET FOR INSTRUMENTS, BY REGION, 2021–2028 (USD MILLION)
7 CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY TECHNOLOGY (Page No. - 98)
    7.1 INTRODUCTION 
          TABLE 25 MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
    7.2 CHEMILUMINESCENCE ENZYME 
           7.2.1 HIGH RELIABILITY OF BLOOD TESTS IN CLINICAL DIAGNOSTICS AND PHARMACEUTICAL RESEARCH TO DRIVE MARKET
                    TABLE 26 MARKET FOR CHEMILUMINESCENCE ENZYME, BY REGION, 2021–2028 (USD MILLION)
    7.3 ELECTROCHEMILUMINESCENCE IMMUNOASSAY 
           7.3.1 INCREASED GENERATION OF EXCITED STATES THROUGH BETTER ELECTRODE VARIATION TO DRIVE MARKET
                    TABLE 27 MARKET FOR ELECTROCHEMILUMINESCENCE IMMUNOASSAY, BY REGION, 2021–2028 (USD MILLION)
    7.4 MICROPARTICLE CHEMILUMINESCENCE IMMUNOASSAY 
           7.4.1 HIGHER COSTS AND GREATER CHANCES OF CROSS-REACTIVITY DUE TO MULTIPLEXING TO LIMIT MARKET
                    TABLE 28 MARKET FOR MICROPARTICLE CHEMILUMINESCENCE IMMUNOASSAY, BY REGION, 2021–2028 (USD MILLION)
8 CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY SAMPLE TYPE (Page No. - 103)
    8.1 INTRODUCTION 
          TABLE 29 MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION)
    8.2 BLOOD 
           8.2.1 HIGH RELIABILITY OF BLOOD TESTS FOR IMMUNOASSAY DIAGNOSTIC PROCEDURES AND HEALTH SCREENING TO DRIVE MARKET
                    TABLE 30 MARKET FOR BLOOD, BY REGION, 2021–2028 (USD MILLION)
    8.3 URINE 
           8.3.1 INCREASING USE IN LAW ENFORCEMENT AND DRUG TESTING CENTERS TO DRIVE MARKET
                    TABLE 31 MARKET FOR URINE, BY REGION, 2021–2028 (USD MILLION)
    8.4 SALIVA 
           8.4.1 CONVENIENCE AND EASY TESTING OF BIOLOGICALLY ACTIVE PARTS OF HORMONES TO DRIVE MARKET
                    TABLE 32 MARKET FOR SALIVA, BY REGION, 2021–2028 (USD MILLION)
    8.5 OTHER SAMPLE TYPES 
                    TABLE 33 MARKET FOR OTHER SAMPLE TYPES, BY REGION, 2021–2028 (USD MILLION)
9 CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY APPLICATION (Page No. - 109)
    9.1 INTRODUCTION 
          TABLE 34 MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
    9.2 INFECTIOUS DISEASES 
           9.2.1 RISING PREVALENCE OF INFECTIOUS DISEASES GLOBALLY AMONG ALL AGE GROUPS TO DRIVE MARKET
                    TABLE 35 MARKET FOR INFECTIOUS DISEASES, BY REGION, 2021–2028 (USD MILLION)
    9.3 ENDOCRINOLOGY 
           9.3.1 RISING INCIDENCES OF DIABETES GLOBALLY TO DRIVE MARKET
                    TABLE 36 MARKET FOR ENDOCRINOLOGY, BY REGION, 2021–2028 (USD MILLION)
    9.4 ONCOLOGY 
           9.4.1 RISING BURDEN OF CANCER AND EMPHASIS ON EARLY DISEASE DIAGNOSIS TO DRIVE MARKET
                    TABLE 37 INCREASING INCIDENCE OF CANCER, BY REGION, 2020 VS. 2030 VS. 2040 (MILLION)
                    TABLE 38 MARKET FOR ONCOLOGY, BY REGION, 2021–2028 (USD MILLION)
    9.5 CARDIOLOGY 
           9.5.1 HIGH BURDEN OF CARDIOVASCULAR DISEASES AMONG ALL AGE GROUPS TO DRIVE MARKET
                    TABLE 39 MARKET FOR CARDIOLOGY, BY REGION, 2021–2028 (USD MILLION)
    9.6 ALLERGY DIAGNOSTICS 
           9.6.1 GROWING PREVALENCE OF ALLERGIES TO REGISTER INCREASED DEMAND FOR CHEMILUMINESCENCE IMMUNOASSAYS
                    TABLE 40 MARKET FOR ALLERGY DIAGNOSTICS, BY REGION, 2021–2028 (USD MILLION)
    9.7 BLOOD SCREENING 
           9.7.1 RISING VOLUME OF BLOOD DONATIONS AND INCREASING INCIDENCES OF BLOOD-RELATED DISORDERS TO DRIVE MARKET
                    TABLE 41 MARKET FOR BLOOD SCREENING, BY REGION, 2021–2028 (USD MILLION)
    9.8 AUTOIMMUNE DISORDERS 
           9.8.1 GROWING PREVALENCE OF AUTOIMMUNE DISORDERS AND RISING ECONOMIC BURDEN OF DISEASE MANAGEMENT TO DRIVE MARKET
                    TABLE 42 MARKET FOR AUTOIMMUNE DISORDERS, BY REGION, 2021–2028 (USD MILLION)
    9.9 BONE & MINERAL DISORDERS 
           9.9.1 HIGH DISORDER PREVALENCE TO INDICATE STRONG GROWTH OPPORTUNITIES FOR IMMUNOASSAYS
                    TABLE 43 MARKET FOR BONE & MINERAL DISORDERS, BY REGION, 2021–2028 (USD MILLION)
    9.1 TOXICOLOGY 
           9.10.1 INCREASED DRUG-OF-ABUSE TESTING AND HIGHER ILLICIT DRUG CONSUMPTION TO DRIVE MARKET
                    TABLE 44 MARKET FOR TOXICOLOGY, BY REGION, 2021–2028 (USD MILLION)
    9.11 NEWBORN SCREENING 
           9.11.1 CHEMILUMINESCENCE IMMUNOASSAYS TO BE ROUTINELY USED AS FIRST-TIER NEWBORN SCREENING PROTOCOL
                    TABLE 45 MARKET FOR NEWBORN SCREENING, BY REGION, 2021–2028 (USD MILLION)
    9.12 THERAPEUTIC DRUG MONITORING 
           9.12.1 RAPID DETECTION TIME AND GOOD SPECIFICITY TO DRIVE MARKET
                    TABLE 46 MARKET FOR THERAPEUTIC DRUG MONITORING, BY REGION, 2021–2028 (USD MILLION)
    9.13 METABOLIC DISORDERS 
           9.13.1 RISING PREVALENCE OF METABOLIC DISORDERS TO DRIVE MARKET
                    FIGURE 37 GLOBAL INCIDENCE OF DIABETES
                    TABLE 47 MARKET FOR METABOLIC DISORDERS, BY REGION, 2021–2028 (USD MILLION)
    9.14 GASTROENTEROLOGY 
           9.14.1 INCREASING INCIDENCE OF GASTROINTESTINAL TRACT INFECTIONS AND SERIOUS GASTRIC DISEASES TO DRIVE MARKET
                    TABLE 48 MARKET FOR GASTROENTEROLOGY, BY REGION, 2021–2028 (USD MILLION)
    9.15 NEUROLOGY 
           9.15.1 EFFECTIVE DETECTION, MONITORING, AND MANAGEMENT OF NEUROLOGICAL DISORDERS TO DRIVE SEGMENT
                    TABLE 49 MARKET FOR NEUROLOGY, BY REGION, 2021–2028 (USD MILLION)
    9.16 RESPIRATORY 
           9.16.1 EASY DETECTION AND DIAGNOSIS OF RESPIRATORY DISEASES TO DRIVE MARKET
                    TABLE 50 MARKET FOR RESPIRATORY, BY REGION, 2021–2028 (USD MILLION)
    9.17 OTHER APPLICATIONS 
                    TABLE 51 MARKET FOR OTHER APPLICATIONS, BY REGION, 2021–2028 (USD MILLION)
10 CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY END USER (Page No. - 129)
     10.1 INTRODUCTION 
             TABLE 52 CHEMILUMINESCENCE IMMUNOASSAY INDUSTRY, BY END USER, 2021–2028 (USD MILLION)
     10.2 HOSPITALS 
             10.2.1 GROWING PATIENT POPULATION AND TESTING VOLUMES TO DRIVE MARKET
                        TABLE 53 MARKET FOR HOSPITALS, BY REGION, 2021–2028 (USD MILLION)
     10.3 CLINICAL LABORATORIES 
             10.3.1 RISING CLINICAL TEST VOLUMES AND REQUIREMENTS TO DRIVE SEGMENT
                        TABLE 54 MARKET FOR CLINICAL LABORATORIES, BY REGION, 2021–2028 (USD MILLION)
     10.4 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES AND CONTRACT RESEARCH ORGANIZATIONS 
             10.4.1 RISING DRUG DISCOVERIES AND CLINICAL STUDIES TO DRIVE MARKET
                        TABLE 55 MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES AND CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2021–2028 (USD MILLION)
     10.5 OTHER END USERS 
             TABLE 56 MARKET FOR OTHER END USERS, BY REGION, 2021–2028 (USD MILLION)
11 CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY REGION (Page No. - 137)
     11.1 INTRODUCTION 
             TABLE 57 CHEMILUMINESCENCE IMMUNOASSAY INDUSTRY, BY REGION, 2021–2028 (USD MILLION)
     11.2 NORTH AMERICA 
                        FIGURE 38 NORTH AMERICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET SNAPSHOT
             TABLE 58 NORTH AMERICA: MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
             TABLE 59 NORTH AMERICA: MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
             TABLE 60 NORTH AMERICA: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
             TABLE 61 NORTH AMERICA: MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION)
             TABLE 62 NORTH AMERICA: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
             TABLE 63 NORTH AMERICA: MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.2.1 IMPACT OF ECONOMIC RECESSION ON NORTH AMERICA
             11.2.2 US
                        11.2.2.1 US to hold largest share in North American chemiluminescence immunoassay market during forecast period
                                     TABLE 64 US: MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                     TABLE 65 US: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                     TABLE 66 US: MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION)
                                     TABLE 67 US: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                     TABLE 68 US: MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.2.3 CANADA
                        11.2.3.1 Rising government initiatives and funding for early disease diagnosis to drive market
                                     TABLE 69 CANADA: ESTIMATED PREVALENCE OF DIABETES
                                     TABLE 70 CANADA: MACROECONOMIC INDICATORS
                                     TABLE 71 CANADA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                     TABLE 72 CANADA: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                     TABLE 73 CANADA: MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION)
                                     TABLE 74 CANADA: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                     TABLE 75 CANADA: MARKET, BY END USER, 2021–2028 (USD MILLION)
     11.3 EUROPE 
             TABLE 76 EUROPE: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
             TABLE 77 EUROPE: MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
             TABLE 78 EUROPE: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
             TABLE 79 EUROPE: MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION)
             TABLE 80 EUROPE: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
             TABLE 81 EUROPE: MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.3.1 IMPACT OF ECONOMIC RECESSION ON EUROPE
             11.3.2 GERMANY
                        11.3.2.1 Growing investments in clinical diagnostics research and increasing government spending on healthcare to drive market
                                     TABLE 82 GERMANY: MACROECONOMIC INDICATORS
                                     TABLE 83 GERMANY: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                     TABLE 84 GERMANY: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                     TABLE 85 GERMANY: MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION)
                                     TABLE 86 GERMANY: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                     TABLE 87 GERMANY: MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.3.3 FRANCE
                        11.3.3.1 Favorable reimbursement policies and increased investments in diagnostics to drive market
                                     TABLE 88 FRANCE: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                     TABLE 89 FRANCE: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                     TABLE 90 FRANCE: MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION)
                                     TABLE 91 FRANCE: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                     TABLE 92 FRANCE: MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.3.4 UK
                        11.3.4.1 Increasing number of accredited clinical laboratories and growing accessibility to IVD tests to drive market
                                     TABLE 93 UK: MACROECONOMIC INDICATORS
                                     TABLE 94 UK: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                     TABLE 95 UK: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                     TABLE 96 UK: MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION)
                                     TABLE 97 UK: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                     TABLE 98 UK: MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.3.5 ITALY
                        11.3.5.1 Growing geriatric population and increasing support for research to drive market
                                     TABLE 99 ITALY: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                     TABLE 100 ITALY: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                     TABLE 101 ITALY: MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION)
                                     TABLE 102 ITALY: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                     TABLE 103 ITALY: MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.3.6 SPAIN
                        11.3.6.1 Rising adoption of technologically advanced immunoassay systems to drive market
                                     TABLE 104 SPAIN: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                     TABLE 105 SPAIN: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                     TABLE 106 SPAIN: MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION)
                                     TABLE 107 SPAIN: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                     TABLE 108 SPAIN: MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.3.7 REST OF EUROPE
                        TABLE 109 REST OF EUROPE: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                        TABLE 110 REST OF EUROPE: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                        TABLE 111 REST OF EUROPE: MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION)
                        TABLE 112 REST OF EUROPE: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                        TABLE 113 REST OF EUROPE: MARKET, BY END USER, 2021–2028 (USD MILLION)
     11.4 ASIA PACIFIC 
                        FIGURE 39 ASIA PACIFIC: CHEMILUMINESCENCE IMMUNOASSAY MARKET SNAPSHOT
             TABLE 114 ASIA PACIFIC: MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
             TABLE 115 ASIA PACIFIC: MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
             TABLE 116 ASIA PACIFIC: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
             TABLE 117 ASIA PACIFIC: MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION)
             TABLE 118 ASIA PACIFIC: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
             TABLE 119 ASIA PACIFIC: MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.4.1 IMPACT OF ECONOMIC RECESSION ON ASIA PACIFIC
             11.4.2 JAPAN
                        11.4.2.1 Growing investments in clinical diagnostics research to drive market
                                     TABLE 120 JAPAN: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                     TABLE 121 JAPAN: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                     TABLE 122 JAPAN: MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION)
                                     TABLE 123 JAPAN: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                     TABLE 124 JAPAN: MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.4.3 CHINA
                        11.4.3.1 China to register highest growth rate in Asia Pacific chemiluminescence immunoassay market during study period
                                     TABLE 125 CHINA: MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                     TABLE 126 CHINA: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                     TABLE 127 CHINA: MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION)
                                     TABLE 128 CHINA: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                     TABLE 129 CHINA: MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.4.4 INDIA
                        11.4.4.1 Growing medical tourism and healthcare infrastructure to drive market
                                     TABLE 130 INDIA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                     TABLE 131 INDIA: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                     TABLE 132 INDIA: MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION)
                                     TABLE 133 INDIA: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                     TABLE 134 INDIA: MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.4.5 SOUTH KOREA
                        11.4.5.1 Rising healthcare spending for innovative IVD technologies to drive market
                                     TABLE 135 SOUTH KOREA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                     TABLE 136 SOUTH KOREA: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                     TABLE 137 SOUTH KOREA: MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION)
                                     TABLE 138 SOUTH KOREA: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                     TABLE 139 SOUTH KOREA: MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.4.6 REST OF ASIA PACIFIC
                        TABLE 140 REST OF ASIA PACIFIC: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                        TABLE 141 REST OF ASIA PACIFIC: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                        TABLE 142 REST OF ASIA PACIFIC: MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION)
                        TABLE 143 REST OF ASIA PACIFIC: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                        TABLE 144 REST OF ASIA PACIFIC: MARKET, BY END USER, 2021–2028 (USD MILLION)
     11.5 REST OF THE WORLD 
             TABLE 145 REST OF THE WORLD: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY REGION, 2021–2028 (USD MILLION)
             TABLE 146 REST OF THE WORLD: MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
             TABLE 147 REST OF THE WORLD: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
             TABLE 148 REST OF THE WORLD: MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION)
             TABLE 149 REST OF THE WORLD: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
             TABLE 150 REST OF THE WORLD: MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.5.1 IMPACT OF ECONOMIC RECESSION ON REST OF THE WORLD
             11.5.2 LATIN AMERICA
                        11.5.2.1 Rising incidence of infectious diseases and increasing geriatric population to drive market
                                     TABLE 151 LATIN AMERICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                     TABLE 152 LATIN AMERICA: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                     TABLE 153 LATIN AMERICA: MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION)
                                     TABLE 154 LATIN AMERICA: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                     TABLE 155 LATIN AMERICA: MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.5.3 MIDDLE EAST & AFRICA
                        11.5.3.1 Lack of skilled laboratory personnel and unfavorable reimbursement policies to limit market
                                     TABLE 156 MIDDLE EAST & AFRICA: CHEMILUMINESCENCE IMMUNOASSAY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                     TABLE 157 MIDDLE EAST & AFRICA: MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
                                     TABLE 158 MIDDLE EAST & AFRICA: MARKET, BY SAMPLE TYPE, 2021–2028 (USD MILLION)
                                     TABLE 159 MIDDLE EAST & AFRICA: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                     TABLE 160 MIDDLE EAST & AFRICA: MARKET, BY END USER, 2021–2028 (USD MILLION)
12 COMPETITIVE LANDSCAPE (Page No. - 221)
     12.1 OVERVIEW 
     12.2 STRATEGIES ADOPTED BY KEY PLAYERS 
             TABLE 161 OVERVIEW OF STRATEGIES ADOPTED BY KEY MANUFACTURERS OF CHEMILUMINESCENCE IMMUNOASSAY PRODUCTS
     12.3 REVENUE ANALYSIS OF TOP MARKET PLAYERS 
             FIGURE 40 REVENUE ANALYSIS OF TOP MARKET PLAYERS IN CHEMILUMINESCENCE IMMUNOASSAY MARKET
     12.4 MARKET SHARE ANALYSIS 
             TABLE 162 CHEMILUMINESCENCE IMMUNOASSAY INDUSTRY: DEGREE OF COMPETITION
             FIGURE 41 CHEMILUMINESCENCE IMMUNOASSAY INDUSTRY SHARE, BY KEY PLAYER (2022)
     12.5 COMPANY EVALUATION MATRIX FOR KEY PLAYERS 
             12.5.1 STARS
             12.5.2 EMERGING LEADERS
             12.5.3 PERVASIVE PLAYERS
             12.5.4 PARTICIPANTS
                        FIGURE 42 CHEMILUMINESCENCE IMMUNOASSAY INDUSTRY: COMPANY EVALUATION MATRIX FOR KEY PLAYERS
     12.6 COMPANY EVALUATION MATRIX FOR SMES/START-UPS 
             12.6.1 PROGRESSIVE COMPANIES
             12.6.2 STARTING BLOCKS
             12.6.3 RESPONSIVE COMPANIES
             12.6.4 DYNAMIC COMPANIES
                        FIGURE 43 CHEMILUMINESCENCE IMMUNOASSAY INDUSTRY: COMPANY EVALUATION MATRIX FOR START-UPS/SMES
     12.7 COMPETITIVE BENCHMARKING 
             TABLE 163 CHEMILUMINESCENCE IMMUNOASSAY INDUSTRY: DETAILED LIST OF KEY START-UPS/SMES
     12.8 COMPANY FOOTPRINT ANALYSIS 
             TABLE 164 OVERALL COMPANY FOOTPRINT
             TABLE 165 COMPANY PRODUCT FOOTPRINT
             TABLE 166 COMPANY REGIONAL FOOTPRINT
     12.9 COMPETITIVE SCENARIO 
             12.9.1 KEY PRODUCT LAUNCHES AND APPROVALS
                        TABLE 167 CHEMILUMINESCENCE IMMUNOASSAY INDUSTRY: KEY PRODUCT LAUNCHES AND APPROVALS, 2020–2023
             12.9.2 KEY DEALS
                        TABLE 168 CHEMILUMINESCENCE IMMUNOASSAY INDUSTRY: KEY DEALS, 2020–2023
             12.9.3 OTHER KEY DEVELOPMENTS
                        TABLE 169 CHEMILUMINESCENCE IMMUNOASSAY MARKET: OTHER KEY DEVELOPMENTS, 2020–2023
13 COMPANY PROFILES (Page No. - 236)
     13.1 KEY PLAYERS 
(Business Overview, Products/Solutions Offered, Recent Developments, SWOT Analysis, Winning Imperatives, Current Focus and Strategies, Threat From Competition, Right to Win)*
             13.1.1 F. HOFFMANN-LA ROCHE LTD.
                        TABLE 170 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW
                        FIGURE 44 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2022)
             13.1.2 DANAHER CORPORATION
                        TABLE 171 DANAHER CORPORATION: COMPANY OVERVIEW
                        FIGURE 45 DANAHER CORPORATION: COMPANY SNAPSHOT (2022)
             13.1.3 SIEMENS HEALTHINEERS AG
                        TABLE 172 SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW
                        FIGURE 46 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2022)
             13.1.4 DIASORIN S.P.A.
                        TABLE 173 DIASORIN S.P.A.: COMPANY OVERVIEW
                        FIGURE 47 DIASORIN S.P.A.: COMPANY SNAPSHOT (2022)
             13.1.5 ABBOTT LABORATORIES
                        TABLE 174 ABBOTT LABORATORIES: COMPANY OVERVIEW
                        FIGURE 48 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2022)
             13.1.6 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.
                        TABLE 175 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.: COMPANY OVERVIEW
                        FIGURE 49 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.: COMPANY SNAPSHOT (2021)
             13.1.7 SYSMEX CORPORATION
                        TABLE 176 SYSMEX CORPORATION: COMPANY OVERVIEW
                        FIGURE 50 SYSMEX CORPORATION: COMPANY SNAPSHOT (2022)
             13.1.8 DIATRON
                        TABLE 177 DIATRON: COMPANY OVERVIEW
                        FIGURE 51 STRATEC SE: COMPANY SNAPSHOT (2022)
             13.1.9 GETEIN BIOTECH, INC.
                        TABLE 178 GETEIN BIOTECH, INC.: COMPANY OVERVIEW
             13.1.10 WERFEN
                        TABLE 179 WERFEN: COMPANY OVERVIEW
             13.1.11 QUIDELORTHO CORPORATION
                        TABLE 180 QUIDELORTHO CORPORATION: COMPANY OVERVIEW
                        FIGURE 52 QUIDELORTHO CORPORATION: COMPANY SNAPSHOT (2022)
             13.1.12 EUROIMMUN MEDIZINISCHE LABORDIAGNOSTIKA AG
                        TABLE 181 EUROIMMUN MEDIZINISCHE LABORDIAGNOSTIKA AG: COMPANY OVERVIEW
*Business Overview, Products/Solutions Offered, Recent Developments, SWOT Analysis, Winning Imperatives, Current Focus and Strategies, Threat From Competition, Right to Win might not be captured in case of unlisted companies.
     13.2 OTHER PLAYERS 
             13.2.1 MERCK KGAA
             13.2.2 TOSOH CORPORATION (TOSOH BIOSCIENCE)
             13.2.3 TRIVITRON HEALTHCARE
             13.2.4 ABNOVA CORPORATION
             13.2.5 ELABSCIENCE
             13.2.6 MACCURA BIOTECHNOLOGY CO., LTD.
             13.2.7 AUTOBIO DIAGNOSTICS CO., LTD
             13.2.8 JIANGSU ZECEN BIOTECH CO., LTD
             13.2.9 RAYTO LIFE AND ANALYTICAL SCIENCES CO., LTD.
             13.2.10 DAAN GENE CO., LTD.
             13.2.11 DYNEX TECHNOLOGIES, INC.
             13.2.12 ZYBIO INC.
             13.2.13 WIENER LABORATORIOS SAIC
             13.2.14 TIANJIN ERA BIOLOGY TECHNOLOGY CO., LTD.
14 APPENDIX (Page No. - 275)
     14.1 DISCUSSION GUIDE 
     14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 
     14.3 CUSTOMIZATION OPTIONS 
     14.4 RELATED REPORTS 
     14.5 AUTHOR DETAILS